...
首页> 外文期刊>Arthritis research & therapy. >Inflammatory back pain in psoriatic arthritis is significantly more responsive to corticosteroids compared to back pain in ankylosing spondylitis: a prospective, open-labelled, controlled pilot study
【24h】

Inflammatory back pain in psoriatic arthritis is significantly more responsive to corticosteroids compared to back pain in ankylosing spondylitis: a prospective, open-labelled, controlled pilot study

机译:与强直性脊柱炎的背痛相比,银屑病性关节炎的炎性背痛对皮质类固醇的反应明显更好:一项前瞻性,开放性,对照的前瞻性研究

获取原文
           

摘要

The efficacy of corticosteroids in patients with psoriatic arthritis (PsA) and inflammatory back pain has not been studied to date. In this controlled trial, we aimed to investigate the comparative performance of corticosteroids in patients with active axial-PsA (AxPsA) versus those with active ankylosing spondylitis (AS). Patients with AxPsA and AS (na?ve to biologic therapies), who not only had clinically active disease, but also had bone marrow oedema on magnetic resonance imaging of the sacroiliac joints, were recruited. Clinically active disease was defined as inflammatory back pain (fulfilling Assessment of Spondyloarthritis International Society (ASAS) expert criteria), with spinal pain score (numerical rating scale 0–10) ≥4 and Bath AS Disease Activity Index (BASDAI) score ≥4 despite taking nonsteroidal anti-inflammatory drugs. Moreover, we recruited a control group of patients with non-inflammatory lower back pain. All patients received a single, intra-muscular dose of depot corticosteroid injection (triamcinolone acetonide 80 mg) at baseline. The intra-muscular corticosteroid option was used to overcome any drug compliance issues. Clinical outcome assessments were made at the following time points: baseline, week 2, and week 4. The primary efficacy end point was mean change in Ankylosing Spondylitis Disease Activity Score (ASDAS) at week 2. Key secondary outcomes were mean change in the BASDAI, Bath Ankylosing Spondylitis Functional Index (BASFI) and Ankylosing Spondylitis Quality of Life (ASQoL) at weeks 2 and 4. In total, 40 patients were recruited (15 with AxPsA, 15 with AS, and 10 controls). At week 2 following corticosteroid treatment, patients with AxPsA had significantly greater improvement in the mean ASDAS compared to patients with AS (1.43 ± 0.39 vs. 1.03 ± 0.30, p = 0.004), and also when compared to controls (p
机译:迄今为止,尚未研究皮质类固醇对银屑病关节炎(PsA)和炎性背痛的疗效。在这项对照试验中,我们旨在研究皮质类固醇在活动性轴向PsA(AxPsA)患者与活动性强直性脊柱炎(AS)患者中的比较性能。招募了AxPsA和AS(未接受过生物疗法)的患者,他们不仅患有临床上活跃的疾病,而且在sa关节的磁共振成像中也患有骨髓水肿。临床活动性疾病定义为炎症性背痛(符合国际脊柱关节炎评估(ASAS)专家标准),脊柱疼痛评分(数字评分等级0–10)≥4,巴斯AS疾病活动指数(BASDAI)评分≥4,尽管服用非甾体类抗炎药。此外,我们招募了非炎症性下腰痛患者的对照组。所有患者在基线时都接受肌肉内单次剂量的皮质类固醇激素注射(曲安奈德80 mg)。肌内注射皮质类固醇激素可以克服药物的依从性问题。在以下时间点进行临床结局评估:基线,第2周和第4周。主要疗效终点是第2周的强直性脊柱炎疾病活动评分(ASDAS)的平均变化。主要的次要结局是BASDAI的平均变化,第2周和第4周时的沐浴强直性脊柱炎功能指数(BASFI)和强直性脊柱炎的生活质量(ASQoL)。总共招募了40名患者(其中15名使用AxPsA,15名使用AS和10名对照)。在皮质类固醇治疗后的第2周,与AS患者相比,AxPsA患者的平均ASDAS改善显着更大(1.43±0.39 vs. 1.03±0.30,p = 0.004),并且与对照组相比(p <0.001) 。在第4周,与AS患者(1.09±0.32 vs. 0.77±0.27,p = 0.007)和对照组相比,AxPsA患者的ASDAS改善趋势相似(p <0.001)。同样,与AS和对照组患者相比,AxPsA患者在第2周时的平均BASDAI,视觉模拟评分脊柱疼痛评分,ASQoL和BASFI显着改善(p <?0.05),并且这种趋势在第4周也基本保持不变。 PsA患者的炎症反应对皮质类固醇的反应明显优于AS患者。这进一步加剧了争论,并增加了越来越多的证据表明AxPsA和AS是不同的实体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号